In the current study, we examine for the first time the effects of fingolimod treatment on MS gene expression signatures using a large panel of inflammatory markers: interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interferon-gamma (INF-γ). This evidence concerns the gene IL6 and myeloid sarcoma.